{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-001555","form_type":"8-K","ticker":"EDSA","cik":"0001540159","company_name":"Edesa Biotech, Inc.","filed_at":"2023-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.507075+00:00","generated_at":"2026-06-19T17:59:19.191520+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Edesa Biotech reports Q1 net loss of $2.33M; FDA Fast Track for ARDS drug","bullets":["Net loss narrowed to $2.33M ($0.13/sh) from $4.38M ($0.33) in prior-year quarter.","Operating expenses down >50% to $2.38M; R&D decreased 66% to $1.36M.","FDA granted Fast Track designation for EB05 (ARDS) after favorable Phase 2 data.","Preliminary Phase 2b results: 1.0% EB01 cream met primary and key secondary endpoints in ACD.","Cash $8.27M; working capital $7.81M; subsequent warrant exercise raised ~$0.77M."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-001555","json":"https://secwatch.observer/filing/0001654954-23-001555.json","markdown":"https://secwatch.observer/filing/0001654954-23-001555.md","text":"https://secwatch.observer/filing/0001654954-23-001555.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540159/000165495423001555/0001654954-23-001555-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540159/000165495423001555/edsa_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T17:59:19.191520+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4a0f5c12097ee0c111776cc325b5728c888f3562","claim":"Edesa Biotech, Inc. reported the three months ended December 31, 2022 results: net income a net loss of $2.33 million, or $0.13 per common share, EPS $0.13 per common share.","evidence_excerpt":"For the quarter ended December 31, 2022, Edesa reported a net loss of $2.33 million, or $0.13 per common share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495423001555/0001654954-23-001555-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2022"},{"label":"Net income","value":"a net loss of $2.33 million, or $0.13 per common share"},{"label":"EPS","value":"$0.13 per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}